Takeda’s Cornelia Zanetti, a recent implant into Greece following stints in Germany, Switzerland, and Singapore, shares her first impressions of the Greek pharma market, and how the Japanese giant is making a difference for Greek patients in oncology, gastroenterology, plasma-derived therapies, and rare diseases. Zanetti also highlights some of the major challenges of the Greek market – notably a punishing clawback and rebate system – and why Takeda has chosen Greece to be an active participant in its global clinical trial operations.
Greece today is an economic wonder with growing GDP, but healthcare expenditure – especially the budget for pharmaceutical medicine – is very low and not increasing in line with overall growth
